Table 2.
Association between serum resistin and all-cause mortality in individual studies and in the combined sample.
| GHS (N = 350) | GMS (N = 698) | FMS (N = 431) | Combined (N = 1,479) | Between-study heterogeneity | |||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||
| Model 1 | 1.55 (1.27–1.90) | 1.9 * 10−5 | 1.38 (1.21–1.57) | 2.3 * 10−6 | 1.31 (1.11–1.56) | 2.0 * 10−3 | 1.39 (1.27–1.53) | 2.4 * 10−12 | 4.2 * 10−1 |
| Model 2 | 1.64 (1.31–2.05) | 1.5 * 10−5 | 1.30 (1.14–1.49) | 6.9 * 10−5 | 1.17 (0.98–1.40) | 8.0 * 10−2 | 1.31 (1.19–1.44) | 2.5 * 10−8 | 2.1 * 10−1 |
| Model 3 | 1.60 (1.26–2.02) | 1.0 * 10−4 | 1.29 (1.11–1.49) | 9.0 * 10−4 | 1.11 (0.92–1.33) | 2.7 * 10−1 | 1.27 (1.14–1.41)§ | 2.1 * 10−5 | 7.7 * 10−2 |
GHS: Gargano Heart Study; GMS: Gargano Mortality Study; FMS: Foggia Mortality Study. HRs (95% CI) are given for the increase of 1 SD of log transformed values of serum resistin. Model 1: unadjusted in individual studies and adjusted for study sample (i.e. GHS, GMS and FMS) in the combined analysis. Model 2: adjusted for sex, age at recruitment, smoking habits, BMI and study sample in the combined analysis. Model 3: adjusted for sex, age at recruitment, smoking habits, BMI, HbA1c, anti-hypertension and anti-dyslipidemia therapies and study sample in the combined analysis. §Robust 95%CI confidence interval (due to the presence of between-study heterogeneity, i.e. for p < 0.10).